Novel imidazobenzazepine derivatives as dual H1/5-HT 2A antagonists for the treatment of sleep disorders

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 17, 2010, Pages 5069-5073

  Gianotti, Massimo ^a   Corti, Corrado ^a   Fratte, Sonia Delle ^a   Di Fabio, Romano ^a   Leslie, Colin P ^a   Pavone, Francesca ^a   Piccoli, Laura ^a   Stasi, Luigi ^a,c   Wigglesworth, Mark J ^b  

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Rotta Research Laboratorium   (Italy)

Author keywords

5 Hydroxytryptamine 2A (5 HT2A) antagonists; Histamine (H1) antagonists; Hypnotics; Sleep disorders; Zwitterions

Indexed keywords

3 [4 (3 2 5H IMIDAZO[1,2 B][2]BENZAZEPIN 11 YL) 1 PIPERAZINYL] 2,2 DIMETHYLPROPANOIC ACID; BENZAZEPINE DERIVATIVE; IMIDAZOBENZAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO SELECTION; IN VIVO STUDY; NONHUMAN; RAT; SLEEP DISORDER; TEMPERATURE MEASUREMENT;

HUMANS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SLEEP DISORDERS;

EID: 77955663989     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.029     Document Type: Article

References (20)

1. J.M. Monti, and D. Monti CNS Drugs 13 2000 87
2. M. Tashiro, H. Mochizuki, K. Iwabuchi, Y. Sakurada, M. Itoh, T. Watanabe, and K. Yanai Life Sci. 72 2002 409
3. D. Popa, C. Léna, V. Fabre, C. Prenat, J. Gingrich, P. Escourrou, M. Hamon, and J. Adrien J. Neurosci. 25 2005 11231
4. A.U. Viola, G. Brandenberger, M. Toussaint, P. Bouhours, J.P. Macher, and R. Luthringer Clin. Neurophysiol. 113 2002 429
5. B. Teegarden, H. Al Shamma, and Y. Xiong Curr. Top. Med. Chem. 8 2008 969
6. S. Fonquerna, and M. Miralpeix Expert Opin. Ther. Patents 16 2006 109
7. J. Bousquet Aria Workshop Group J. Allergy Clin. Immunol. 108 2001 S147
8. For example: (a) Edgar, D. M.; Hangauer, D. G.; Leighton, H. J.; Mignot, E. J. M.; White, J. F.; Solomon, M.; Shiosaki, K. Patent WO2005/103041, 2005
9. (b) Edgar, D. M.; Hangauer, D. G.; White, J. F.; Solomon, M.; Shiosaki, K. Patent WO2006/034414, 2006.
10. S. Sullivan, and C. Guilleminault Expert Opin. Emerging Drugs 14 2009 411
11. J.G. Verkade, and P.B. Kisanga Aldrichim. Acta 37 2004 3
12. G. Campiani, S. Butini, S. Gemma, V. Nacci, C. Fattorusso, B. Catalanotti, G. Giorgi, A. Cagnotto, M. Goegan, T. Mennini, P. Minetti, M.A. Di Cesare, D. Mastroianni, N. Scafetta, B. Galletti, M.A. Stasi, M. Castorina, L. Pacifici, O. Ghirardi, O. Tinti, and P. Carminati J. Med. Chem. 45 2002 344
13. M.J. Wigglesworth, K.J. Lawless, D.J. Standing, E.K. Mackenzie, V.R. Kitchen, F. Mckay, E. Ward, S.J. Brough, M. Stylianou, F.R. Jewitt, A.M. Mclaren-Douglas, M.I. Jowet, N. Tamayama, D. Finnigan, J. Ding, and A. Wise J. Biomol. Screen. 13 2008 354
14. S.J. Brough, and P. Shah Use of Aequorin for G-Protein Coupled Receptor Hit Identification and Compound Profiling W. Leifert, The Methods in Molecular Biology S52, Methods and Protocols 5th ed. 2009 Humana Press New York 181
15. S. Kantor, R. Jakus, B. Balogh, A. Benko, and G. Bagdy Br. J. Pharmacol. 142 2004 1332
16. M.I. Smith, D.C. Piper, M.S. Duxon, and N. Upton Pharmacol., Biochem. Behav. 71 2002 599
17. 1A/B ≤ 6 (aequorin assay).
18. All work involving animals was carried out in accordance with European directive 86/609/EEC governing animal welfare and protection, which is acknowledged by Italian Legislative Decree No. 116, 27 January 1992, and according to internal review performed by the GlaxoSmithKline Committee on Animal Research & Ethics (CARE) and to the company Policy on the Care and Use of Laboratory Animals.
19. P. Breedveld, J.H. Beijnen, and J.H.M. Schellens Trends Pharmacol. Sci. 27 2006 17
20. The effects of 9 were assessed using telemetric recording of electroencephalogram (EEG) and electromyogram (EMG) in the rat. Simultaneous recording of EEG and EMG allows the accurate derivation of the sleep parameters. The test compound effects were assessed for 5 h, in the active phase, starting at circadian time [CT] 18 (light off at circadian time [CT] 12) of the rat light-dark cycle. CT18 was chosen to allow a maximal window to assess the hypnotic effects of the compound.